Article

Full Access

Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers

Corresponding Author

David J. Flavell

The Simon Flavell Leukaemia Research laboratory, University Department of Pathology, Southampton S09 4XY, UK

The Simon Flavell Leukaemia Research laboratory, University Department of Pathology, Southampton S09 4XY, UK. Fax: 44 (0)703 704906Search for more papers by this author

Deborah A. Boehm,

Deborah A. Boehm

The Simon Flavell Leukaemia Research laboratory, University Department of Pathology, Southampton S09 4XY, UK

Search for more papers by this author

Keiko Okayama,

Keiko Okayama

The Simon Flavell Leukaemia Research laboratory, University Department of Pathology, Southampton S09 4XY, UK

Search for more papers by this author

Janice A. Kohler,

Janice A. Kohler

University Department of Child Health, Southampton General Hospital, Southampton S09 4XY, UK

Search for more papers by this author

Sopsamor N. U. Flavell,

Sopsamor N. U. Flavell

The Simon Flavell Leukaemia Research laboratory, University Department of Pathology, Southampton S09 4XY, UK

Search for more papers by this author

David J. Flavell,

Corresponding Author

David J. Flavell

The Simon Flavell Leukaemia Research laboratory, University Department of Pathology, Southampton S09 4XY, UK

The Simon Flavell Leukaemia Research laboratory, University Department of Pathology, Southampton S09 4XY, UK. Fax: 44 (0)703 704906Search for more papers by this author

Deborah A. Boehm,

Deborah A. Boehm

The Simon Flavell Leukaemia Research laboratory, University Department of Pathology, Southampton S09 4XY, UK

Search for more papers by this author

Keiko Okayama,

Keiko Okayama

The Simon Flavell Leukaemia Research laboratory, University Department of Pathology, Southampton S09 4XY, UK

Search for more papers by this author

Janice A. Kohler,

Janice A. Kohler

University Department of Child Health, Southampton General Hospital, Southampton S09 4XY, UK

Search for more papers by this author

Sopsamor N. U. Flavell,

Sopsamor N. U. Flavell

The Simon Flavell Leukaemia Research laboratory, University Department of Pathology, Southampton S09 4XY, UK

Search for more papers by this author

First published: 1 August 1994

https://doi.org/10.1002/ijc.2910580317

Citations: 18

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

A SCID mouse model of human T-ALL has been used to determine the in vivo therapeutic efficacy of two anti-CD7-saporin immunotoxins constructed with either a hindered (HB2-SMPT-Sap) or non-hindered (HB2-SPDP-Sap) disulphide bond between antibody and saporin. Groups of 10 SCID mice were injected intravenously (i.v.) with 2 × 10⁶ human T-ALL HSB-2 cells followed seven days later by i.v. injection with either a single dose or with 3 doses of HB2-SPDP-Sap or HB2-SMPT-Sap given on alternate days. Control groups received equivalent sham injections of PBS or molar equivalent amounts of unconjugated HB2 antibody + saporin. Animals receiving a single dose of HB2-SMPT-Sap showed better survival than animals receiving a single dose of HB2-SPDP-Sap but the difference was not shown to be significant by log-rank analysis. When given as a triple dose both immunotoxins performed similarly. Comparison of single-dose with triple-dose IT therapy revealed that the therapeutic effect of a triple dose of HB2-SPDP-Sap was significantly better than that of single dose, but this was not the case with HB2-SMPT-Sap. Pharmacokinetic studies of HB2-SPDP-Sap and HB2-SMPT-Sap in normal and HSB-2 leukaemia bearing SCID mice failed to reveal any difference in clearance rates for these two IT's. We conclude from these studies that there is no therapeutic advantage to be gained from constructing the HB2-Sap IT with a hindered disulphide bond in this particular model of human T-ALL.

References

Adams, R. A., Pothier, L., Flowers, A., Lazarus, H., Farber, S. and Foley, G. E., The question of stemlines in human acute leukemia. Comparison of cells isolated in vitro and in vivo from a patient with acme lymphoblastic leukemia. Exp. Cell Res., 62, 5–10 (1970).
10.1016/0014-4827(79)90504-4
CAS PubMed Web of Science® Google Scholar
Amlot, P. L., Stone, M. J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M. and Richardson, J., A Phase-I study of an anti-CD22-deglycosylated Ricin-A-chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 82, 2624–2633 (1993).
PubMed Web of Science® Google Scholar
Andriole, G. L., Mule, J. J., Hansen, C. T., Lineham, W. M. and Rosenberg, S. A., Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenially immunodeficient mice. J. Immunol., 135, 2911–2913 (1985).
CAS PubMed Web of Science® Google Scholar
Blakey, D. C., Watson, G. J., Knowles, P. P., and Thorpe, P. E., Effect of chemical deglycosylation of Ricin-A-chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of Ricin-A-chain and anti-Thy 1.1 antibody. Cancer Res., 47, 947–952 (1987).
CAS PubMed Web of Science® Google Scholar
Fishwild, D. M., Aberle, S., Bernhard, S. L. and Kung, A. H. C., Efficacy of an anti-CD7 Ricin-A-chain immunoconjugate in a novel murine model of human T-cell leukaemia. Cancer Res., 82, 3056–3062 (1992).
Google Scholar
Flavell, D. J., Cooper, S., Morland, B. and Flavell, S. U., Characteristics and performance of a bispecific F(ab'γ)₂ antibody for delivering saporin to a CD7⁺ human acute T-cell leukaemia cell line. Brit. J. Cancer, 64, 274–280 (1991).
10.1038/bjc.1991.291
CAS PubMed Web of Science® Google Scholar
Laemmli, U. K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227, 680–683 (1970).
10.1038/227680a0
CAS PubMed Web of Science® Google Scholar
Lambert, J. M., Senter, P. D., Yau-Young, A., Blattler, W. A. and Goldmacher, V. S., Purified immunotoxins that are reactive with human lymphoid cells. MAbs conjugated to the RIPs gelonin and PAP. J. boil. Chem., 260, 12035–12041 (1983).
PubMed Web of Science® Google Scholar
Morland, B. J., Barley, J., Boehm, D., Flavell, S. U., Ghaleb, R., Kohler, J. A., Okayama, K., Wilkins, B. and Flavell, D. J., Effectiveness of HB2(anti-CD7)-saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in SCID mice. Brit. J. Cancer, 69, 279–285 (1994).
10.1038/bjc.1994.52
CAS PubMed Web of Science® Google Scholar
Stirpe, F., Gasperi-Campani, A., Barbieri, L., Falasca, A., Abbondanza, A. and Stevens, W. A., Ribosome-inactivating proteins from the seeds of Saponaria officinalis L. (soapwort), of Agrostemma githago L. (corn cockle) and of Asparagus officinalis L. (asparagus), and from the latex of Hura crepitans L. (sandbox tree). Biochem. J., 216, 617–625 (1983).
10.1042/bj2160617
CAS PubMed Web of Science® Google Scholar
Stross, W. P., Warnke, R. A., Flavell, D. J., Flavell, S. U., Simmons, D., Gatter, K. C. and Mason, D. Y., Molecule detected in formalin-fixed tissue by antibodies MT1, DF-T1 and L60 (Leu-22) corresponds to CD43 antigen. J. clin. Pathol., 42, 953–961 (1989).
10.1136/jcp.42.9.953
CAS PubMed Web of Science® Google Scholar
Thorpe, P. E., Brown, A. N. F., Bremner, J. A. G., Jr., Foxwell, B. M. J. and Stirpe, F., An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. J. nat. Cancer Inst., 75, 151–159 (1985).
CAS PubMed Web of Science® Google Scholar
Thorpe, P. E., Wallace, P. M., Knowles, P. P., Relf, M. G., Brown, A. N. F., Watson, G. J., Knyba, R. E., Wawrzynczak, E. J. and Blakey, D. C., New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res., 47, 5924–5931 (1987).
CAS PubMed Web of Science® Google Scholar
Thorpe, P. E., Wallace, P. M., Knowles, P. P., Relf, M. G., Brown, A. N. K., Watson, G. J., Knyba, R. E., Wawrzynczak, E. J. and Blakey, D. C., Improved anti-tumor effects of immunotoxins prepared with deglycosylated ricin A chain and hindered disulphide linkages. Cancer Res., 48, 6396–6403 (1988).
CAS PubMed Web of Science® Google Scholar
Uckun, F. M., Immunotoxins for the treatment of leukaemia. Brit. J. Haematol., 85, 435–438 (1993).
10.1111/j.1365-2141.1993.tb03329.x
CAS PubMed Web of Science® Google Scholar
Vitetta, E. S., Stone, M., Amlot, P., Fay, J., May, R., Till, M., Newman, J., Clark, P., Collins, R., Cunningham, D., Ghetie, V., Uhr, J. W. and Thorpe, P. E., Phase-I immunotoxin trial in patients with B-cell lymphoma. Cancer Res., 81, 4032–4058 (1991).
Google Scholar
Vitetta, E. S., Thorpe, P. E. and Uhr, J. W., Immunotoxins: magic bullets or misguided missiles? Immunol. Today, 14, 252–259 (1993).
10.1016/0167-5699(93)90041-I
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume58, Issue3

1 August 1994

Pages 407-414

Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers

Abstract

References

Citing Literature

References

Related

Information